Interestingly, the migration of breast cancer cells was increased by UDP in a dose-dependent manner; this elevation was significantly inhibited by the selective P2Y6 antagonist MRS2578 in both the scratch (Figure 2C) and Transwell (Figure 2D) assays. This evidence concerns the gene P2RY6 and breast carcinoma.